natgillin/translations-raw huggingface dataset:
Chewable tablet 
Tableta za žvakanje.
10 tablets 30 tablets 60 tablets 180 tablets 
180 tableta.
Previcox 227 mg chewable tablets Firocoxib 
Previcox 227 mg tablete za žvakanje.
ANNEX II A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE D. STATEMENT OF THE MRLs 
DODATAK II A. NOSITELJ(I) ODOBRENJA ZA PROIZVODNJU ODGOVORAN(I) ZA PUŠTANJE SERIJE U PROMET
Previcox 57 mg chewable tablets Firocoxib 
Previcox 57 mg tablete za žvakanje.
SPECIAL STORAGE PRECAUTIONS 
Posebne mjere opreza za primjenu na životinjama
- 2nd injection: after 3-4 weeks. 
- Druga injekcija: nakon 3-4 tjedna.
a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals. 
a) će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
In cattle and sheep - 1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young cattle and sheep born to immune animals). 
Za goveda i ovce - Prva injekcija: od 1 mjeseca starosti (ili od 2,5 mjeseca starosti u mladih goveda i ovaca rođenih od imunih životinja).
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal product on the whole or part of their territory if it is established that: 
Sukladno članku 71. Direktive 2001/82/EK i Europskog Parlamenta i Vijeća s izmjenama i dopunama države članice u skladu sa nacionalnim zakonodavstvom mogu zabraniti proizvodnju, uvoz, posjedovanje, prodaju, opskrbu i/ili primjenu imunoloških veterinarsko-medicinskih proizvoda na cijelom svom teritoriju ili na jednom njegovom dijelu ako je utvrđeno da:
The duration of immunity for cattle and sheep is 1 year after the primary vaccination course. 
Trajnost imuniteta kod goveda i ovaca je 1 godinu nakon prvog cijepljenja.
The excipients (including adjuvants) listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required. 
Pomoćne tvari (uključujući adjuvanse) navedene u odjeljku 6.1 Sažetka opisa svojstava su dopuštene tvari za koje, kako je navedeno u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010. za koje se MRL ne zahtijeva.
The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009. 
Djelatne tvari koje se sastoje od tvari biološkog podrijetla, namijenjene su za izazivanje aktivne imunosti na koje se ne primjenjuju odredbe Uredbe (EK) br. 470/2009.
Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 
Laboratory od Lyon Porte des Alpes Rue de l'Aviation,
A transient increase in body temperature, normally not exceeding an average of 1.1 °C, may occur within 24 hours after vaccination. 
Prolazno povišenje tjelesne temperature, obično ne više od 1,1 °C, može se javiti unutar 24 sata nakon cijepljenja.
The import, sale, supply and/or use of BTVPUR AlSap 8 is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy. 
Uvoz, prodaja, opskrba i/ili primjena BTVPUR AlSap 8 je ili može biti zabranjena u određenim državama članicama na cijelom teritoriju ili na jednom njegovom dijelu sukladno nacionalnim odredbama zaštite zdravlja životinja.
Any person intending to import, sell, supply and/or use BTVPUR AlSap 8 must consult the relevant Member State's competent authority on the current vaccination policies prior to the import, sale, supply and/or use. 
Tko namjerava uvesti, prodavati, opskrbljivati i/ili primjenjivati BTVPUR AlSap 8 mora konzultirati nadležno tijelo odnosne države članice u pogledu važećih odredbi o cijepljenju prije uvoza, prodaje, opskrbe i/ili primjene.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml of vaccine contains: 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka doza od 1 ml cjepiva sadrži:
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis. 
Stoga se odluka o primjeni ovog cjepiva prije, odnosno poslije primjene bilo kojeg drugog veterinarsko-medicinskog proizvoda mora donositi od slučaja do slučaja.
Each dose of 1 ml of vaccine contains: 
Svaka doza od 1 ml cjepiva sadrži:
Pharmacotherapeutic group: bluetongue virus vaccine, ATCvet code: QI04AA02 (sheep) and QI02AA08 (cattle). 
Farmakoterapijska grupa: cjepivo protiv virusa bolesti plavog jezika, ATCvet kod: QI04AA02 (ovce) i QI02AA08 (goveda).
* (below the level of detection by the validated RT-PCR method at 3.14 log10 RNA copies/ml, indicating no infectious virus transmission) 
* (vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na 3,14 log10 RNA copies/ml, ukazuje na odsutnost virusa zaraze)
The safety and the efficacy of the vaccine has not been established in breeding males. 
Neškodljivost i djelotvornost cjepiva nije ustanovljena na rasplodnim mužjacima.
Onset of immunity has been demonstrated 3 weeks after the primary vaccination course. 
Početak imuniteta nastupa 3 tjedna nakon prvog cijepljenja.
4.11 Withdrawal period Zero days. 
4.11 Karencija Nula dana.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 10 doses (10 ml) 
SADRŽAJ, TEŽINA, VOLUMEN IL BROJ DOZA 10 doza (10 ml).
Active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by Bluetongue virus serotype 8 (BTV 8). 
Aktivna imunizacija ovaca i goveda za sprečavanje viremije* i za smanjenje kliničkih znakova uzrokovanih virusom bolesti plavog jezika serotip 8 (BTV 8).
Can be used during pregnancy and lactation in cows. 
Može se primijeniti tijekom graviditeta i laktacije u krava.
MARKETING AUTHORISATION NUMBER(S) EU/2/09/094/001 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/09/094/001
Polypropylene bottle of 50 or 100 ml with butyl elastomere closure. 
Polipropilenska bočica od 50 ili 100 ml s čepom iz butilnog elastomera.
In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/ or national Competent Authorities on the current vaccination policies against Bluetongue virus (BTV). 
U toj kategoriji životinja cjepivo treba primijeniti samo po procjeni odnosa koristi/rizika od strane odgovornog veterinara i/ili nadležnih tijela sukladno važećim odredbama o cijepljenju protiv virusa bolesti plavog jezika (BTV).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Bottle of 10 and 50 ml 
OSNOVNI PODACI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKOVANJA Bočica od 10 ml i 50 ml
Vaccination may be followed by a small local swelling at the injection site (at most 32 cm²) for a short period (at most 14 days). 
Nakon cijepljenja se može na mjestu uboda javiti prolazni mali otok (najviše 32 cm²) koji se povlači za 14 dana.
Shelf life after first opening the immediate packaging: immediately after broaching. 
Rok valjanosti nakon prvog otvaranja unutarnjeg pakovanja: upotrijebiti odmah nakon otvaranja.
Aluminium hydroxide Purified saponin Silicon antifoam Phosphate buffer Glycine buffer Water for injection 
Aluminijev hidroksid Pročišćeni saponin Silikonsko sredstvo protiv pjenjenja Fosfatni pufer
The vaccine contains inactivated bluetongue virus serotype 8 with aluminium hydroxide and saponin adjuvants. 
Cjepivo sadrži inaktivirani virus bolesti plavog jezika serotip 8 s aluminijevim hidroksidom i saponinom kao adjuvansima.
• Revaccination Annual. 
• Docjepljivanje: Godišnje.
Administer one dose of 1 ml subcutaneously according to the following vaccination scheme: 
Injicirajte jednu dozu od 1 ml cjepiva subkutano u skladu sa sljedećim rasporedom cijepljenja:
Shelf life of the veterinary medicinal product as package for sale (50-ml and 100-ml bottles): 2 years. 
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju (bočice od 50 ml i 100 ml): 2 godine.
It induces an active and specific immunity against Bluetongue virus serotype 8 in the vaccinated animal. 
Inducira aktivnu i specifičnu imunost protiv virusa bolesti plavog jezika serotip 8 u cijepljenoj životinji
Shelf life of the veterinary medicinal product as package for sale (10-ml bottle): 18 months. 
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju (bočica od 10 ml): 18 mjeseci.
BATCH NUMBER Lot{number} 
BROJ PROIZVODNE SERIJE Lot {broj}
Type I glass bottle of 10 ml with butyl elastomere closure. 
Staklena bočica (staklo tip I) od 10 ml s čepom iz butilnog elastomera.
PACKAGE SIZE 100 doses (100 ml) 
VELIČINA PAKOVANJA 100 doza (100 ml)
Manufacturer responsible for batch release: MERIAL 
Nositelj odobrenja za proizvodnju odgovoran za puštanje proizvodne serije: MERIAL
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each dose of 1 ml of vaccine contains Bluetongue virus serotype 8 antigen ................. ≥ 2.1 log10 pixels 
NAVOĐENJE DJELATNIH I DRUGIH TVARI Svaka doza od 1 ml cjepiva sadrži virusni antigen protiv bolesti plavog jezika serotip 8 ≥ 2,1 log10 piksela
PACKAGE LEAFLET FOR: BTVPUR AlSap 8 suspension for injection 
UPUTA O VMP: BTVPUR AlSap 8 suspenzija za injekciju
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each dose of 1 ml of vaccine contains: BTV8 antigen............................................... ≥ 2.1 log10 pixels* Aluminium hydroxide, Saponin, qs 1 dose (*) (*) see package leaflet 
NAVOĐENJE DJELATNIH I DRUGIH TVARI Svaka doza od 1 ml cjepiva sadrži: BTV8 antigen ..................................................... ≥ 2,1 log10 pixels* Aluminij hidroksid, pročišćeni saponin (*)Vidjeti uputu o VMP
METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous use 
NAČIN I PUT(EVI) PRIMJENE Subkutana primjena.
Aluminium hydroxide .................................................................................................................... 2.7 mg Saponin ........................................................................................................................................ 30 HU** (**) Haemolytic units 
Aluminijev hidroksid ...................................................................................................................... 2,7 mg saponin ........................................................................................................................................ 30 HU** (**) Hemolitičke jedinice
QUANTITY OF THE ACTIVE SUBSTANCE(S) BTV 8 antigen ...................................................................................................... ≥ 2.1 log10 pixels/dose 
KOLIČINA DJELATNE(IH) TVARI BTV 8 antigen ...................................................................................................... ≥ 2,1 log10 pixels/doza
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double- dose of the vaccine. 
Nakon primjene dvostruke doze cjepiva nisu primijećene nuspojave osim onih već spomenutih u odjeljku 4.6.
Bluetongue virus serotype 8 antigen ........................................................................... ≥ 2.1 log10 pixels* Aluminium hydroxide .................................................................................................................... 2.7 mg Saponin ........................................................................................................................................ 30 HU** (*) antigen content (VP2 protein) by immuno-assay (**) Haemolytic units 
Virusni antigen protiv bolesti plavog jezika serotip 8 ................................................. ≥ 2,1 log10 pixels* Aluminijev hidroksid ...................................................................................................................... 2,7 mg Saponin ........................................................................................................................................ 30 HU** (*) sadržaj antigena (VP2 protein) po imunotestu (**) Hemolitičke jedinice
NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 8, suspension for injection 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA BTVPUR AlSap 8, suspenzija za injekciju.
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 8 suspension for injection 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA BTVPUR AlSap 8 suspenzija za injekciju.
SC. Read the package leaflet before use. 
s.c Pročitati uputu o VMP prije primjene.
SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2 °C-8 °C). 
11. POSEBNI UVIJETI ČUVANJA Čuvati i prevoziti rashlađeno (2 °C-8 °C).
No adverse reactions except those mentioned in section ‘Adverse Reactions' were observed after the administration of a double-dose of vaccine. 
Nakon primjene dvostruke doze cjepiva nisu primijećene nuspojave osim onih već spomenutih u odjeljku “Nuspojave”.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE 
UVIJETI ILI OGRANIČENJA ODOBRENJA ZA STAVLJANJE U PROMET U POGLEDU OPSKRBE I PRIMJENE
Bluetongue virus serotype 8 antigen ........................................................................... ≥ 2.1 log10 pixels* (*) Antigen content (VP2 protein) by immuno-assay Adjuvants: 
Virusni antigen protiv bolesti plavog jezika serotip 8 ................................................. ≥ 2,1 log10 pixels* (*) Sadržaj antigena (VP2 protein) po imunotestu
WITHDRAWAL PERIOD Withdrawal period: zero days. 
KARENCIJA Karencija: nula dana.
Box of 10 bottles of 50 doses (10 x 50 ml). 
Kutija s 10 bočica od 50 doza (10 x 50 ml).
Box of 1 bottle of 50 doses (1 x 50 ml). 
Kutija s 1 bočicom od 50 doza (1 x 50 ml).
PHARMACEUTICAL FORM Suspension for injection 
Voda za injekcije
Box of 10 bottles of 100 doses (10 x 100 ml). 
Kutija s 10 bočica od 100 doza (10 x 100 ml).
Excipients: 
Adjuvans:
Box of 1 bottle of 10 doses (1 x 10 ml). 
Kutija s 1 bočicom od 10 doza (1 x 10 ml).
Box of 1 bottle of 100 doses (1 x 100 ml). 
Kutija s 1 bočicom od 100 doza (1 x 100 ml).
Annual. 
ROK VALJANOSTI
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKI DJELATNE TVARI I NOSITELJ
Actos pioglitazone 
Actos pioglitazon
The tablets should be swallowed with water. 
Tableta se treba progutati s vodom.
Almost 7,000 patients received Actos in all of the studies combined. 
Gotovo 7000 bolesnika primalo je Actos u svim ispitivanjima zajedno.
Further studies also looked at long-term use of Actos. 
Daljnja ispitivanja također su proučavala dugoročnu upotrebu lijeka Actos.
The full EPAR for Actos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Actos nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Actos: 
Ostale informacije o lijeku Actos:
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed. 
Tu će dozu možda biti potrebno povećati nakon jednog ili dva tjedna do 45 mg jednom dnevno ako je potrebna bolja kontrola glukoze u krvi (šećera).
What measures are being taken to ensure the safe and effective use of Actos? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Actos?
The European Commission granted a marketing authorisation valid throughout the European Union, for Actos on 13 October 2000. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Actos na snazi u Europskoj uniji od 13. listopada 2000.
The recommended starting dose of Actos is 15 or 30 mg once a day. 
Preporučena početna doza lijeka Actos je od 15 do 30 mg jednom dnevno.
It is used in addition to diet and exercise as follows: 
Upotrebljava se kao dodatak prehrani i tjelovježbi na sljedeći način:
If Actos is used in combination with other diabetes medicines, other side effects may occur. 
Ako se Actos upotrebljava u kombinaciji s drugim lijekovima za dijabetes, mogu se javiti i druge nuspojave.
Actos is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. 
Actos se koristi za liječenje dijabetesa tipa 2 u odraslih (u dobi od 18 godina ili više), osobito bolesnika s prekomjernom tjelesnom težinom.
This is a summary of the European public assessment report (EPAR) for Actos. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Actos.
Actos is a medicine that contains the active substance pioglitazone. 
Actos je lijek koji sadrži djelatnu tvar pioglitazon.
For more information about treatment with Actos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Actos pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Actos. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Actos.
It must also not be used in patients who have or have had bladder cancer or those with blood in the urine that has not yet been investigated. 
Također se ne smije se primjenjivati u bolesnika koji imaju ili su imali rak mjehura ili u bolesnika koji imaju krv u mokraći koja još nije ispitana.
At subsequent reviews prescribers should confirm that benefits to patients are maintained. 
U naknadnim procjenama liječnici koji propisuju terapiju trebali bi potvrditi da su se održale koristi za bolesnike.
The most common side effects with Actos (seen in between 1 and 10 patients in 100) are upper respiratory tract infection (colds), hypoaesthesia (reduced sense of touch), visual disturbance, bone fractures and increased weight. 
Najčešće su nuspojave pri uzimanju lijeka Actos (zabilježene u između 1 i 10 na 100 bolesnika) infekcija gornjeg respiratornog trakta (prehlade), hipoestezija (smanjen osjet dodira), poremećaj vida, prijelomi kostiju i povećana tjelesna težina.
The company that markets Actos will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting. 
Tvrtka koja lijek Actos stavlja u promet osigurat će edukativni materijal za liječnike koji propisuju taj lijek koji će obuhvaćati informacije o mogućem riziku od srčanog zastoja i raka mjehura u liječenjima koja sadrže pioglitazon, kriterijima za odabir bolesnika te potrebi za redovitim procjenjivanjem učinaka terapije i prekida liječenja ako bolesnici više nemaju koristi od nje.
Actos must not be used in patients who have problems with their liver, patients who have had heart failure (when the heart does not work as well as it should) or patients with diabetic ketoacidosis (a complication of diabetes). 
Actos se ne smije primjenjivati u bolesnika koji imaju problema s jetrom, u bolesnika koji su imali srčani zastoj (kada srce ne radi kako bi trebalo) ili u bolesnika s dijabetičkom ketoacidozom (komplikacija urokovana dijabetesom).
The active substance in Actos, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Djelatna tvar u lijeku Actos, pioglitazon, čini stanice (masti, mišića i jetre) osjetljivijima na inzulin, što znači da se tijelo bolje koristi inzulinom koji proizvodi.
Treatment with Actos should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. 
Nakon tri do šest mjeseci liječenja potrebno je procijeniti liječenje lijekom Actos i prekinuti ga u bolesnika u kojih nisu vidljive dostatne koristi.
The CHMP decided that Actos's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi od lijeka Actos nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. 
Sva su ispitivanja mjerila razinu tvari u krvi koja se naziva glikozilirani hemoglobin (HbA1c), koji ukazuje na to koliko se dobro kontrolira glukoza u krvi.
As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes. 
Posljedica je smanjenje razine glukoze u krvi, što pomaže pri kontroli dijabetesa tipa 2.
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. 
Dijabetes tipa 2 bolest je pri kojoj gušterača ne proizvodi dovoljno inzulina za kontrolu razine glukoze u krvi ili pri kojoj se tijelo ne može učinkovito koristiti inzulinom.
Why has Actos been approved? 
Zašto je Actos odobren?
What is the risk associated with Actos? 
Koji su rizici povezani s lijekom Actos?
Actos also improved the glucose control obtained in type 2 diabetes when it was added to existing treatment with a sulphonylurea, insulin or metformin, or the combination of metformin and a sulphonylurea. 
Actos je također poboljšao kontrolu glukoze postignutu u dijabetesa tipa 2 kad je dodan postojećem liječenju sulfonilurejom, inzulinom ili metforminom, ili kombinacijom metformina i sulfonilureje.
Actos led to a decrease in the level of HbA1c, indicating that blood glucose levels had been reduced at doses of 15, 30 and 45 mg. Actos on its own was shown to be as effective as metformin and gliclazide. 
Actos je doveo do smanjenja razine HbA1c, ukazujući na to da su razine glukoze u krvi smanjene pri primjeni doza od 15, 30 i 45 mg.
• together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin. 
• zajedno s inzulinom u bolesnika koje se ne može zadovoljavajuće kontrolirati samo inzulinom i koji ne mogu uzimati metformin.
What is Actos? 
Što je Actos?
• together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite treatment with two medicines by mouth; 
• zajedno s metforminom i sulfonilurejom u bolesnika koje se ne može zadovoljavajuće kontrolirati unatoč liječenju dvama lijekovima oralnom primjenom;
• in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone; 
• u kombinaciji s metforminom u bolesnika u kojih se ne može postići zadovoljavajuća kontrola samo metforminom, ili sulfonilurejom (drugom vrstom lijeka protiv dijabetesa) ako metformin nije prikladan u bolesnika koji se ne mogu zadovoljavajuće kontrolirati samo sulfonilurejom;
Some studies also looked at combining Actos with a sulphonylurea, insulin or metformin, or with the combination of metformin and a sulphonylurea. 
U nekim se ispitivanjima također proučavala kombinacija lijeka Actos sa sulfonilurejom, inzulinom ili metforminom, ili s kombinacijom metformina i sulfonilureje.